(Q35587424)

English

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study

scientific article published on 29 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

author name string

R Ruiter

1

1 reference

Europe PubMed Central

9 August 2017

L E Visser

2

1 reference

Europe PubMed Central

9 August 2017

M P P van Herk-Sukel

3

1 reference

Europe PubMed Central

9 August 2017

J W W Coebergh

4

1 reference

Europe PubMed Central

9 August 2017

H R Haak

5

1 reference

Europe PubMed Central

9 August 2017

P H Geelhoed-Duijvestijn

6

1 reference

Europe PubMed Central

9 August 2017

S M J M Straus

7

1 reference

Europe PubMed Central

9 August 2017

R M C Herings

8

1 reference

Europe PubMed Central

9 August 2017

B H Ch Stricker

9

1 reference

Europe PubMed Central

9 August 2017

publication date

29 September 2011

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

55

1 reference

Europe PubMed Central

9 August 2017

1

1 reference

Europe PubMed Central

9 August 2017

51-62

1 reference

Europe PubMed Central

9 August 2017

https://scigraph.springernature.com/pub.10.1007/s00125-011-2312-4

0 references

Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Long-term effects of insulin glargine on the risk of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Diabetes mellitus and risk of breast cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Mechanisms linking obesity to insulin resistance and type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Diabetes mellitus and risk of bladder cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

27 July 2018

Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Diabetes and cancer: a consensus report.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Diabetes therapy and cancer risk: causal effects and other plausible explanations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Diabetes mellitus type 2 - an independent risk factor for cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Does insulin therapy promote, reduce, or have a neutral effect on cancers?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Insulin glargine and malignancy: an unwarranted alarm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Does diabetes therapy influence the risk of cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Diabetes mellitus and risk of prostate cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228952

26 September 2018

Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes;59:1254-1260

1 reference

https://pubmed.ncbi.nlm.nih.gov/21956710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://pubmed.ncbi.nlm.nih.gov/21956710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/21956710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21956710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proliferative effects of insulin analogues on mammary epithelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21956710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

https://pubmed.ncbi.nlm.nih.gov/21956710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes and cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21956710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21956710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-011-2312-4

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35587424&oldid=1580279236"